Tack L J W, Brachet C, Beauloye V, Heinrichs C, Boros E, De Waele K, van der Straaten S, Van Aken S, Craen M, Lemay A, Rochtus A, Casteels K, Beckers D, Mouraux T, Logghe K, Van Loocke M, Massa G, Van de Vijver K, Syryn H, Van De Velde J, De Baere E, Verdin H, Cools M
Department of Internal Medicine and Pediatrics, Ghent University, Pediatric Endocrinology Service, Ghent University Hospital, Belgium, Ghent.
Université libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B), Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Paediatric Endocrinology Unit, Brussels, Belgium.
Hum Reprod Open. 2023 Dec 1;2023(4):hoad047. doi: 10.1093/hropen/hoad047. eCollection 2023.
What is the long-term outcome of individuals born with bilateral testicular regression (BTR) in relation to its underlying etiology?
Statural growth and pubertal development are adequate with incremental doses of testosterone replacement therapy (TRT); however, penile growth is often suboptimal, especially in those with a suspected genetic etiology (i.e. heterozygous variants) or a micropenis at birth.
BTR is a rare and poorly understood condition. Although a vascular origin has been postulated, heterozygous missense variants in have been attributed to the phenotype as well. How these various etiologies impact the clinical phenotype, gonadal histology and outcome of BTR remains unclear.
For this cross-sectional study, individuals with BTR were recruited in eight Belgian pediatric endocrinology departments, between December 2019 and December 2022. A physical exam was performed cross-sectionally in all 17 end-pubertal participants and a quality of care questionnaire was completed by 11 of them. Exome-based panel testing of 241 genes involved in gonadal development and spermatogenesis was performed along with a retrospective analysis of presentation and management. A centralized histological review of gonadal rests was done for 10 participants.
PARTICIPANTS/MATERIALS SETTING METHODS: A total of 35 participants (33 with male, 1 with female, and 1 with non-binary gender identity) were recruited at a mean age of 15.0 ± 5.7 years.
The median age at presentation was 1.2 years [0-14 years]. Maternal gestational complications were common (38.2%), with a notably high incidence of monozygotic twin pregnancies (8.8%). Heterozygous (likely) pathogenic missense variants in (p.Arg334Trp and p.Arg308Gln) were found in three participants. No other (likely) pathogenic variants were found. All three participants with a variant had a microphallus at birth (leading to female sex assignment in one), while only six of the remaining 31 participants without a variant (19.4%) had a microphallus at birth (information regarding one participant was missing). Testosterone therapy during infancy to increase penile growth was more effective in those without versus those with a variant. The three participants with a variant developed a male, female, and non-binary gender identity, respectively; all other participants identified as males. TRT in incremental doses had been initiated in 25 participants (median age at start was 12.4 years). Final height was within the target height range in all end-pubertal participants; however, 5 out of 11 participants (45.5%), for whom stretched penile length (SPL) was measured, had a micropenis (mean adult SPL: 9.6 ± 2.5). Of the 11 participants who completed the questionnaire, five (45.5%) reported suboptimal understanding of the goals and effects of TRT at the time of puberty induction. Furthermore, only 6 (54.5%) and 5 (45.5%) of these 11 participants indicated that they were well informed about the risks and potential side effects of TRT, respectively. Histological analysis of two participants with variants suggested early disruption of gonadal development due to the presence of Müllerian remnants in both and undifferentiated gonadal tissue in one. In eight other analyzed participants, no gonadal remnants were found, in line with the BTR diagnosis.
The limitations of this study include the relatively small sample size (n = 35) and the few individuals with variants (n = 3). Furthermore, data on the SPL were often missing, due to this being undocumented or refused by participants.
TRT provides adequate statural growth, even when initiated in late adolescence, thus providing time for physicians to explore the patients' gender identity if needed. However, sufficient and understandable information regarding the effects and side effects of TRT is required throughout the management of these patients. SPL remains suboptimal in many individuals and could be improved by TRT during infancy to mimic the physiological mini-puberty. An environmental origin in some participants is supported by the high incidence of gestational complications (38.2%) and by the three monozygotic twin pregnancies discordant for the BTR phenotype. Individuals with a heterozygous variant have a more severe phenotype with severely restricted penile growth until adulthood. Histological analysis confirmed as a gonadal development, rather than a BTR-related, gene.
STUDY FUNDING/COMPETING INTERESTS: Funding was provided by the Belgian Society for Pediatric Endocrinology and Diabetology (BESPEED) and by Ghent University Hospital under the NucleUZ Grant (E.D.B.). M.C. and E.D.B. are supported by an FWO senior clinical investigator grant (1801018N and 1802220N, respectively). The authors report no conflicts of interest.
N/A.
双侧睾丸退化(BTR)患者的长期预后与其潜在病因有何关系?
递增剂量的睾酮替代疗法(TRT)可使身高增长和青春期发育正常;然而,阴茎生长往往不理想,尤其是那些具有疑似遗传病因(即杂合变异)或出生时患有小阴茎的患者。
BTR是一种罕见且了解甚少的疾病。尽管推测其起源于血管,但 中的杂合错义变异也被认为与该表型有关。这些不同病因如何影响BTR的临床表型、性腺组织学和预后仍不清楚。
研究设计、规模、持续时间:在这项横断面研究中,2019年12月至2022年12月期间,在比利时的八个儿科内分泌科招募了患有BTR的个体。对所有17名青春期后期参与者进行了横断面体格检查,其中11人完成了护理质量问卷。对241个参与性腺发育和精子发生的基因进行了基于外显子组的panel检测,并对临床表现和治疗进行了回顾性分析。对10名参与者的性腺残留组织进行了集中组织学检查。
参与者、材料、设置、方法:共招募了35名参与者(33名男性、1名女性和1名非二元性别者),平均年龄为15.0±5.7岁。
就诊时的中位年龄为1.2岁[0 - 14岁]。母亲孕期并发症很常见(38.2%),单卵双胎妊娠的发生率尤其高(8.8%)。在三名参与者中发现了 中的杂合(可能)致病性错义变异(p.Arg334Trp和p.Arg308Gln)。未发现其他(可能)致病变异。所有三名携带 变异的参与者出生时均患有小阴茎(其中一名导致女性性别指定),而其余31名未携带 变异的参与者中只有六名(19.4%)出生时患有小阴茎(一名参与者的信息缺失)。婴儿期进行睾酮治疗以促进阴茎生长,对未携带 变异的参与者比对携带 变异的参与者更有效。三名携带 变异的参与者分别发展为男性、女性和非二元性别认同;所有其他参与者均认同为男性。25名参与者开始接受递增剂量的TRT(开始时的中位年龄为12.4岁)。所有青春期后期参与者的最终身高均在目标身高范围内;然而,在测量了阴茎拉伸长度(SPL)的11名参与者中,有5名(45.5%)患有小阴茎(成人平均SPL:9.6±2.5)。在完成问卷的11名参与者中,有五名(45.5%)报告在青春期诱导时对TRT的目标和效果理解欠佳。此外,在这11名参与者中,分别只有6名(54.5%)和5名(45.5%)表示他们充分了解TRT的风险和潜在副作用。对两名携带 变异的参与者进行的组织学分析表明,由于两人均存在苗勒氏残留物且其中一人存在未分化的性腺组织,性腺发育早期受到破坏。在其他八名接受分析的参与者中,未发现性腺残留,这与BTR诊断一致。
局限性、谨慎原因:本研究的局限性包括样本量相对较小(n = 35)以及携带 变异的个体较少(n = 3)。此外,由于参与者未记录或拒绝提供,SPL数据常常缺失。
TRT即使在青春期后期开始也能使身高充分增长,从而为医生在必要时探索患者的性别认同提供时间。然而,在这些患者的整个治疗过程中,需要提供关于TRT的效果和副作用的充分且易懂的信息。许多个体的SPL仍然不理想,婴儿期进行TRT以模拟生理性小青春期可能会有所改善。一些参与者中存在环境起源的观点得到了孕期并发症高发生率(38.2%)以及三例BTR表型不一致的单卵双胎妊娠的支持。携带杂合 变异的个体具有更严重的表型,直到成年阴茎生长都受到严重限制。组织学分析证实 是一个与性腺发育相关而非与BTR相关的基因。
研究资金/利益冲突:资金由比利时儿科内分泌学和糖尿病学协会(BESPEED)以及根特大学医院根据NucleUZ资助(E.D.B.)提供。M.C.和E.D.B.分别获得了弗拉芒研究基金会(FWO)高级临床研究人员资助(分别为1801018N和1802220N)。作者声明无利益冲突。
无。